Author Topic: FDA wants more restrictions on fluoroquinolone use  (Read 52 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8629
  • MS diagnosed 1980
  • Location: Pacific Northwest
FDA wants more restrictions on fluoroquinolone use
« on: May 21, 2016, 04:14:28 pm »
The frequent UTIs many people with MS are apt to get have often been treated with Cipro prescriptions. Now the prescribing of fluoroquinolone drugs (like Cipro) may be restricted because of possible severe side effects.

From NEJM Journal Watch, May 21, 2016:

FDA Calls for More Restrictions on Fluoroquinolone Use

By Kristin J. Kelley

Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

The risks for "disabling and potentially permanent" side effects associated with systemic fluoroquinolone antibacterials (e.g., ciprofloxacin, moxifloxacin) generally outweigh the benefits in patients with sinusitis, bronchitis, and uncomplicated urinary tract infections, the FDA warned late last week. Fluoroquinolones should only be used for these indications when patients don't have other treatment options, the agency said.

Side effects can compromise the nerves, central nervous system, tendons, muscles, and joints. Symptoms may include confusion; hallucinations; joint, muscle, and tendon pain; or a tingling sensation (i.e., "pins and needles").

The action follows advisory panel recommendations made in late 2015 for stronger label warnings. The labels were previously updated in 2013 to warn of increased risk for peripheral neuropathy. Additionally, in 2008, a boxed warning was added to note risks for tendinitis and tendon rupture.

« Last Edit: May 23, 2016, 02:28:25 pm by agate »
MS Speaks--online for 14 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post April 21, 2020, 08:38:55 pm
by agate
0 Replies
Last post May 27, 2020, 08:58:50 pm
by agate